GEQIX
Price
$16.68
Change
+$0.04 (+0.24%)
Updated
Nov 13 closing price
VIVAX
Price
$69.44
Change
+$0.09 (+0.13%)
Updated
Nov 13 closing price
Ad is loading...

GEQIX vs VIVAX

Header iconGEQIX vs VIVAX Comparison
Open Charts GEQIX vs VIVAXBanner chart's image
Glenmede Equity Income
Price$16.68
Change+$0.04 (+0.24%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$69.44
Change+$0.09 (+0.13%)
VolumeN/A
CapitalizationN/A
GEQIX vs VIVAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GEQIX vs. VIVAX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GEQIX is a Buy and VIVAX is a StrongSell.

FUNDAMENTALS
Fundamentals
VIVAX has more cash in the bank: 184B vs. GEQIX (19M). VIVAX pays higher dividends than GEQIX: VIVAX (2.25) vs GEQIX (1.65). GEQIX was incepted earlier than VIVAX: GEQIX (8 years) vs VIVAX (32 years). GEQIX is a more actively managed with annual turnover of: 21.00 vs. VIVAX (10.00). GEQIX has a lower initial minimum investment than VIVAX: GEQIX (0) vs VIVAX (3000). VIVAX annual gain was more profitable for investors over the last year : 29.30 vs. GEQIX (18.83). VIVAX return over 5 years is better than : 53.44 vs. GEQIX (46.61).
GEQIXVIVAXGEQIX / VIVAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years32 years-
Gain YTD15.55318.99382%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets19M184B0%
Annual Yield % from dividends1.652.2573%
Returns for 1 year18.8329.3064%
Returns for 3 years7.6122.5234%
Returns for 5 years46.6153.4487%
Returns for 10 yearsN/A113.82-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXPL1.150.05
+4.55%
NextPlat Corp
TRUP53.751.34
+2.56%
Trupanion
CRNT2.550.02
+0.79%
Ceragon Networks Ltd
FICO2348.10-1.90
-0.08%
Fair Isaac Corp
DNLI29.90-1.68
-5.32%
Denali Therapeutics